San Diego Regenerative Medicine Institute (SDRMI), a nonprofit independent biomedical research institute, was founded to facilitate the transition of human stem cell research towards stem cell therapy to provide the next generation of cell-based therapeutic solutions for unmet medical challenges in world-wide major health problems. SDRMI is committed to the leading position in pluripotent human embryonic stem cell (hESC) research and cell-based regenerative medicine by developing groundbreaking hESC technology platforms and innovative hESC-based regenerative medicine approaches, including:PluriXcel Human Stem Cell Technology Platforms: provide proprietary clinical-grade translating capabilities to address key challenges to traditional medicine & biofabrication, and offers currently the only available human cell sources in large quantity and high quality with adequate cellular capacity to regenerate the contractile heart muscle and the neuron circuitry, overcoming major bottlenecks for tissue repair & biofabrication, including: PluriXcel-DCS (defined culture system) Platform; PluriXcel-SMI (small molecule induction)-Heart Platform; PluriXcel-SMI-Neuron Platform.Xcel Cell Therapy Product Prototypes: provide the only available human cell sources in commercial scales with adequate cellular pharmacologic utility and capacity to regenerate the neurons and contractile heart muscles, vital for neurological and heart repair for a wide range of incurable or hitherto untreatable neurological and cardiovascular diseases in the clinical setting, including: Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Alzheimer disease, spinal cord injury (SPI), traumatic brain injury (TBI), stroke, myocardial infarction, cardiomyopathy, and heart failure.